← Back to Investors

V-Bio Ventures

V-Bio Ventures is a Belgian life sciences venture capital firm investing in innovative European biotechnology companies. The firm focuses on therapeutics, diagnostics, and medical devices, with deep roots in the Flanders biotech ecosystem including connections to VIB, one of Europe's premier life sciences research institutes.

Location
Ghent, Belgium
Founded
2015
AUM
€300M+
Investment Range
€1M - €15M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b

Investment Thesis

V-Bio Ventures invests in European life sciences companies developing breakthrough technologies with strong scientific foundations. They focus on companies emerging from leading research institutions, with particular expertise in companies spun out of VIB and other Flemish research centers. The firm provides strategic support and access to their extensive network of industry partners.

Team

Partners / Managing Directors

  • Jan Van de Winkel, PhD - Partner
  • Danny Crabbe - Partner
  • Marc Borms - Partner

Other Key Team Members

  • Sophie Heck - Investment Director
  • Scientific Advisory Board with expertise across therapeutics areas

Focus Areas

  • Oncology
  • Immunology
  • Neuroscience
  • Rare Diseases
  • Gene & Cell Therapy
  • Diagnostics
  • Medical Devices

Notable Portfolio Companies

  • argenx - Antibody-based therapies (IPO 2017, major success)
  • Ablynx - Nanobody therapeutics (acquired by Sanofi for €3.9B)
  • Orionis Biosciences - Chimeric protein therapeutics
  • Aelin Therapeutics - Peptide therapeutics
  • Molecubes - Preclinical imaging

Notable Exits

  • argenx - IPO (2017, NASDAQ: ARGX, market cap >$30B)
  • Ablynx - Acquired (2018, acquired by Sanofi for €3.9B)
  • Ogeda - Acquired (2017, acquired by Astellas for €500M)
  • ActoGeniX - Acquired (acquired by Intrexon)

Sources